🔎 Trials Near Me

Home › Acute Myeloid Leukemia › Colorado

Pag-aaral pangklinika para sa Acute Myeloid Leukemia sa Colorado

22 pag-aaral para sa Acute Myeloid Leukemia ang naghahanap ng mga kalahok sa mga site sa Colorado.

Mga Lungsod sa Colorado

Opisyal na teksto ng pag-aaral (English)

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

  • Rocky Mountain Regional VA Medical Center, Aurora
  • UCHealth University of Colorado Hospital, Aurora
  • Penrose-Saint Francis Healthcare, Colorado Springs
  • at 15 pa
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
Edad 40 hanggang 75 · Lahat ng kasarian · Na-update Okt 2, 2026 · NCT05334069

Pharmacokinetic Study of Venetoclax Tablets Crushed and Dissolved Into a Solution

  • Children's Hospital Colorado, Aurora
Nagre-recruitObservasyonal na pag-aaral
Edad 0 hanggang 38 · Lahat ng kasarian · Na-update Okt 1, 2026 · NCT06131801

A Study of Bleximenib, Venetoclax and Azacitidine For Treatment of Participants With Newly Diagnosed Acute Myeloid Leukemia (AML)

  • Rocky Mountain Cancer Centers, Aurora
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06852222

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

  • Children's Hospital Colorado, Aurora
  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
Nagre-recruitPhase 3
6 Months – 21 Years · Lahat ng kasarian · Na-update Set 17, 2026 · NCT04293562

A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

  • University of Colorado, Aurora
Nagre-recruitPhase 1/2
30 Days · Lahat ng kasarian · Na-update Set 16, 2026 · NCT04065399

Xylitol Dental Wipes for the Reduction of Bloodstream Infection Risk in Children With Acute Myeloid Leukemia

  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
Nagre-recruitPhase 3
Edad 1 hanggang 25 · Lahat ng kasarian · Na-update Set 4, 2026 · NCT07022678

CD64 CAR T Cell Therapy in Adults With Relapsed and/or Refractory AML

  • University of Colorado Hospital, Aurora
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Set 2, 2026 · NCT07347418

CER-1236 in Patients With Acute Myeloid Leukemia (AML), Myelodysplastic Syndrome (MDS), and Myelofibrosis (MF)

  • Colorado Blood Cancer Institute, Denver
Nagre-recruitPhase 1
Edad 18 hanggang 85 · Lahat ng kasarian · Na-update Ago 26, 2026 · NCT06834282

Eganelisib as Monotherapy and in Combination With Cytarabine in Relapsed/Refractory AML

  • Anshutz Cancer Pavilion, Aurora
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT06533761

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

  • Children's Hospital Colorado, Aurora
  • Rocky Mountain Hospital for Children-Presbyterian Saint Luke's Medical Center, Denver
Nagre-recruitPhase 1/2
Hanggang edad 22 · Lahat ng kasarian · Na-update Ago 25, 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  • Children's Hospital Colorado, Aurora
Nagre-recruitPhase 3
29 Days – 21 Years · Lahat ng kasarian · Na-update Ago 24, 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

  • University of Colorado, Aurora
  • Colorado Blood Cancer Institute, Denver
Nagre-recruitPhase 3
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT07007312

Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • Colorado Blood Cancer Institute, Denver
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 20, 2026 · NCT06001788

Study of Revumenib, Azacitidine, and Venetoclax in Pediatric and Young Adult Patients With Refractory or Relapsed Acute Myeloid Leukemia

  • Children's Hospital Colorado, Aurora
Nagre-recruitPhase 1
Edad 1 hanggang 30 · Lahat ng kasarian · Na-update Ago 3, 2026 · NCT06177067

A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs)

  • Children's Hospital Colorado, Aurora
  • University of Colorado Hospital, Aurora
  • Presbyterian St. Luke's/Colorado Blood Cancer Institute, Denver
Nagre-recruitObservasyonal na pag-aaral
Lahat ng edad · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT01351545

A Phase 1/2 Study of Enzomenib (DSP-5336) in Patients With Acute Leukemia (Horizen-1)

  • Colorado Blood Cancer Institute, Denver
Nagre-recruitPhase 1/2
Edad 12 pataas · Lahat ng kasarian · Na-update Mar 24, 2026 · NCT04988555

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

  • University of Colorado, Aurora
  • Colorado Blood Cancer Institute, Denver
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT05735184

Study of NMS-03597812 in Adult Patients With Relapsed/Refractory Acute Myeloid Leukemia

  • Rocky Mountain Cancer Centers, Aurora
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Okt 31, 2025 · NCT06549790

Specialty Compared to Oncology Delivered Palliative Care for Patients With Acute Myeloid Leukemia

  • University of Colorado Denver I Anschutz Medical Campus, Denver
Nagre-recruitMalugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 120 · Lahat ng kasarian · Na-update Hul 25, 2025 · NCT05237258

APVO436 Phase 1b/2 Study in Patients With Newly Diagnosed AML

  • Colorado Blood Cancer Institute, Denver
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update May 11, 2025 · NCT06634394

Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.